Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

IMMUNICY-1

Overview

The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide.

SparkCures ID 1096
Trial Phase Phase 1
Enrollment 12 Patients
Treatments
Tags
Trial Sponsors
  • Celyad Therapeutics
NCT Identifier

NCT04613557
ACCEPTING

This trial is currently open and accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  1. Documented diagnosis of MM with relapsed or refractory disease to at least two prior MM treatment regimens which should include exposure to IMiD and PIs either alone or in combination.
  2. Presence of measurable disease as per International Myeloma Working Group (IMWG) Response Criteria
  3. Eastern Cooperative Oncology Group (ECOG) below or equal 2
  4. Adequate hematologic, renal, hepatic, pulmonary, and cardiac function

Exclusion Criteria:

  1. History or presence of clinically relevant central nervous system (CNS) pathology.
  2. Autologous stem cell transplant within 12 weeks of registration or an allogeneic stem cell transplant within 6 months of starting study treatment.
  3. Any investigational agent within 3 weeks prior to the initiation of the non-myeloablative preconditioning chemotherapy).
  4. Prior systemic therapy for MM within 14 days prior to the initiation of the non-myeloablative preconditioning chemotherapy.
  5. Prior treatment with any BCMA-targeted therapy and which has not achieved at least a partial response.
🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Moffitt Cancer Center Magnolia Campus

Tampa, FL

New York University Langone Medical Center Laura and Isaac Perlmutter Cancer Center

New York, NY

Florida
Moffitt Cancer Center Magnolia Campus

Tampa, FL

  • Recruiting
New York
New York University Langone Medical Center Laura and Isaac Perlmutter Cancer Center

New York, NY

  • Recruiting
International Locations

This trial has active trial locations in countries outside of the United States.

Our system currently only provides clinical trial matching services for myeloma patients in the United States.

You can view this clinical trial's international locations by visiting ClinicalTrials.gov. Please be aware that the government website may include information that is inaccurate and/or out-of-date.

View International Centers

Published Results

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress

June 11, 2021

Safety and tolerability data:

Of the six patients dosed at the first two dose levels (30×106 and 100×106 cells per infusion):

  • No dose limiting toxicity (DLT), Graft-versus Host disease (GvHD) or CAR T-cell-related encephalopathy syndrome (CRES) were observed in the first two dose cohorts.
  • One cytokine release syndrome (CRS) Grade 1 (fever) requiring hospitalization occurred 10 days post CYAD-211 administration in patient 1 (dose level 1) who achieved a partial response (PR).
  • One patient experienced an anemia adverse event (Grade 3) and neutropenia (Grade 4) possibly related to CYAD-211.

Clinical activity:

Of the five evaluable patients at the first two dose levels (30×106 and 100×106 cells per infusion):

  • Two patients achieved a PR. Both patients were ‘triple-therapy exposed’ (previously treated with an immunomodulator (IMiD), a proteasome inhibitor and an anti-CD38 antibody).
  • The three additional patients had stable disease (SD).

Cell kinetics:

  • CYAD-211 cells were detected by PCR-based methods in all six patients from dose cohorts 1 and 2.
  • Cell engraftment was seen in all three patients at dose level 2 at a similar magnitude. In addition, preliminary data suggest that all patients in dose level 2 showed deep lymphodepletion. Across dose level 1, the depth of lymphodepletion appears to correlate with the degree of observed systemic CAR T engraftment.

Next steps:

  • Enrollment in dose cohort 3 (300×106 cells per infusion) is ongoing.
  • Additional clinical data from the dose escalation trial are expected during second half 2021.
  • shRNA technology platform to be highlighted at upcoming virtual R&D Day in Q3 2021.
Read More

Resources

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message